title: The ability of human bispecific anti-idiotype antibody to elicit humoral and cellular immune responses in mice.
abstract: Our goal is to compare the immunogenicity and the extent of immunologic reactivity between bispecific and mono anti-idiotype vaccines. We previously obtained two human anti-Id antibody fragments fuse5-G22, fuse5-I50 by phage display technology which were mimics of the antigens from nasopharyngeal carcinoma cell line (HNE2). In this study, we developed and characterized a bispecific anti-Id antibody vaccine G22-I50 and its parent monovalent antibody vaccines G22 and I50. The efficacy of G22-I50, G22, and I50 as tumor vaccines was evaluated in Balb/c mice with three injections of these vaccines adjuvanted with Freund's adjuvant. Mice immunized with G22-I50 exhibited comparable levels of antibody titers and stronger binding inhibition capabilities. Spleen cells from G22-I50-immunized mice gave a significant proliferative response and higher expression level of IFN-gamma and IL-2.These results suggested that bispecific anti-Id antibody vaccine was able to induce more powerful humoral and cell-mediated immune responses, which might make it to be a potential vaccine candidate for the therapy of nasopharyngeal carcinoma.
authors.affiliation: Tumor Immunobiology Laboratory of Cancer Research Institution, Central South University, Changsha 410078, Hunan, China.
authors.forename: Jia-Jia
authors.initials: JJ
authors.lastname: Wang
authors.forename: Yue-Hui
authors.initials: YH
authors.lastname: Li
authors.forename: Yan-Hong
authors.initials: YH
authors.lastname: Liu
authors.forename: Jie
authors.initials: J
authors.lastname: Song
authors.forename: Feng-Jie
authors.initials: FJ
authors.lastname: Guo
authors.forename: Ya-Lin
authors.initials: YL
authors.lastname: Li
authors.forename: Guan-Cheng
authors.initials: GC
authors.lastname: Li
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology* / Q000627:therapeutic use; D018033:Antibodies, Bispecific / Q000276:immunology* / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000097:blood / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D002277:Carcinoma / Q000276:immunology / Q000628:therapy; D049109:Cell Proliferation; D005260:Female; D005620:Freund's Adjuvant / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D007376:Interleukin-2 / Q000096:biosynthesis / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009303:Nasopharyngeal Neoplasms / Q000276:immunology / Q000628:therapy; D013154:Spleen / Q000276:immunology
chemical_list: D000888:Antibodies, Anti-Idiotypic; D018033:Antibodies, Bispecific; D000912:Antibodies, Neoplasm; D019496:Cancer Vaccines; D007376:Interleukin-2; D007371:Interferon-gamma; D005620:Freund's Adjuvant